 I do think there are a lot of companies looking at mechanisms outside of amyloid. And even when we talked with Eli Lilly after their approval, they talked about how amyloid targeting is really just the first step. It's not the end-all be-all way to treat Alzheimer's. There are other ways they're looking at and other companies are looking at. And so, yeah, I think there are a lot of approaches that are being researched right now going forward.